Skip to main content
. 2022 Dec 26;10(36):13264–13273. doi: 10.12998/wjcc.v10.i36.13264

Table 2.

The feasibility and safety of prophylactic treatment, n (%)

Outcome

Stricture rate 0 (0)
Main complication 1 (7)
Procedure-related bleeding 0 (0)
Procedure-related perforation 0 (0)
Newly diagnosed diabetes or aggravation of diabetes 0 (0)
Pepticulcer 0 (0)
Adrenocortical insufficiency 0 (0)
Aggravation of osteoporosis or fracture 0 (0)
Infection 1 (7)
Corticosteroid related mental disorders 0 (0)
Follow-up period (mo), median (range) 13 (6-28)
Residual 0 (0)
Recurrence 0 (0)